MILWAUKEE, June 3, 2022 /PRNewswire/ -- Ademi LLP is investigating Turning Point Therapeutics (NASDAQ:TPTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myer. 

Click here to learn how to join the action: https://www.ademilaw.com/case/turning-point-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges Turning Point Therapeutics' financial outlook and prospects are excellent and yet Turning Point Therapeutics holders will receive only $76.00 per share in an all-cash transaction for a total consideration of $4.1 billion in equity value. The transaction agreement unreasonably limits competing bids for Turning Point Therapeutics by imposing a significant penalty if Turning Point Therapeutics accepts a superior bid. Turning Point Therapeutics insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Turning Point Therapeutics' board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Turning Point Therapeutics.

If you own Turning Point Therapeutics common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/turning-point-therapeutics-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Ademi LLP                                                          
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-turning-point-therapeutics-inc-has-obtained-a-fair-price-in-its-transaction-with-bristol-myer-301560895.html

SOURCE Ademi LLP